Spotify Breaks Ground with First-Ever Cannabis Ads in Partnership with Cresco Labs

Spotify Breaks Ground with First-Ever Cannabis Ads in Partnership with Cresco Labs

Spotify, the world’s leading music streaming service, has always been known for its bold and innovative approach. In a groundbreaking move, Spotify has become the first streaming platform to embrace cannabis advertising through its new collaboration with Cresco Labs (CRLBF).

The campaign marks a significant convergence of two influential industries: cannabis and music streaming. Spotify boasts an impressive user base of over 220 million subscribers as of the first quarter of 2023, according to Statista, making it a prime target for advertisers seeking broad reach.

Cresco Labs, headquartered in Chicago, Illinois, is the owner of the renowned Sunnyside cannabis dispensary brand. The company believes that advertising on Spotify, one of the most frequented music streaming platforms, will effectively connect with cannabis enthusiasts—an unsurprising association given the historical link between music and marijuana.

Cory Rothschild, National Retail President of Cresco Labs, expressed the company’s enthusiasm for this groundbreaking partnership: “Audio streaming services represent a major opportunity for brands to reach large audiences in a targeted manner, and we’re excited to collaborate with Spotify to launch the first-ever cannabis ads from our Sunnyside national retail brand. Our Sunnyside advertising strategy is built on a data ecosystem enabling best-in-class targeting and measurement. Spotify’s platform will enable our marketing team to target our ads compliantly and profitably to our core shoppers in Illinois where we have a leading share in retail.”

Rothschild also highlighted the broader significance of this partnership, stating, “This important partnership is not only a step in normalizing cannabis, but it also showcases the sophistication and quality of marketing that we have unlocked at Cresco Labs.”

The Cresco ad campaign is expected to center on the Sunnyside “shopping experience.” It will feature 30-second audio advertisements and in-app digital banners, primarily focusing on the company’s proprietary e-commerce platform.

Spotify has earned a reputation for being an affordable platform for advertisers, with per-ad prices starting at just $250.

In this innovative partnership, Spotify and Cresco Labs are not only pushing boundaries but also contributing to the evolving landscape of cannabis advertising, marking a significant step toward its normalization.

 

Source: The Street

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Cannabis Delivery Services: Bringing Accessibility to Cannabis Enthusiasts Across the US

Legalizing cannabis in the United States has opened doors to new possibilities for consumers, but accessibility remains a concern for many. For some, reaching a dispensary can be challenging due to transportation limitations, health issues, or the need for childcare. In response to these challenges, cannabis delivery services have emerged as a godsend for those seeking a convenient and hassle-free way to access their favorite products.

Proximity Matters: How Closeness to Cannabis Stores Drives Legal Market Sales in Canada

New research on Canada’s regulated cannabis market has shed light on consumer preferences and their impact on marijuana sales. The study, set to be published in the Journal of Studies on Alcohol and Drugs, explores the relationship between consumers’ proximity to government-regulated cannabis stores and their purchasing decisions.

New Jersey Cannabis Regulators Propose New Permits to Facilitate Research Partnerships with Dispensaries

New Jersey’s cannabis regulatory authorities are currently open to public feedback regarding an innovative proposal aimed at introducing a novel permit. This permit would enable “clinically focused” dispensaries to collaborate with research institutions, facilitating comprehensive studies on cannabis using the products they cultivate and sell to patients.

Newsletter

Cannabis Milestone: Vermont’s Thriving Marketplace Surpasses $100 Million in Sales

Cannabis Milestone: Vermont’s Thriving Marketplace Surpasses $100 Million in Sales

Vermont’s cannabis marketplace is celebrating its first year of operation, and the results are nothing short of impressive. With projections indicating retail sales for the current fiscal year reaching over $100 million, the state has reaped more than $20 million in additional revenue. This milestone underscores the success of Vermont’s foray into regulated cannabis sales.

In October of the previous year, the Vermont Cannabis Control Board took the pivotal step of granting licenses to a select few retail stores. Since then, the Control Board has been tirelessly working to expand its reach, and the fruits of their labor are evident with the issuance of nearly 70 retail licenses, with more in the pipeline.

James Pepper, the Chairman of the Control Board, is enthusiastic about the positive response from Vermont consumers to the state-controlled cannabis marketplace. He notes that consumers have demonstrated a strong preference for regulated products. They seek out the educational resources provided, desire transparency through labeling, and appreciate the consistency and variety offered within the state’s regulated cannabis market.

Pepper is optimistic about the financial windfall that these cannabis sales will bring to the state. The substantial new revenue is slated to make a significant impact on vital programs. The chairman highlights that the funds will primarily bolster “after school” programs, providing opportunities for Vermont’s youth to engage in constructive activities during their free time. Additionally, the revenue will be channeled into drug education and prevention programs, serving as a proactive measure to address substance abuse and related issues.

As Vermont’s cannabis marketplace gains momentum, it not only offers an opportunity for responsible adult use but also contributes to the betterment of the state’s communities. The success of this venture demonstrates the effectiveness of regulated cannabis sales in meeting consumer demand while simultaneously benefiting important social initiatives. Vermont’s journey into the world of legalized cannabis continues to set an example for responsible and profitable cannabis regulation across the nation.

For More Information, Visit https://www.vermontpublic.org/local-news/2023-09-18/vermonts-cannabis-marketplace-has-been-open-for-a-year-and-is-generating-millions

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Cannabis Unveiled: Exploring the Wellness Benefits of a Green Revolution

Cannabis once shrouded in controversy and stigma, is experiencing a remarkable transformation in public perception and legal status. Beyond its recreational use, cannabis is increasingly being recognized for its potential health and wellness benefits. This article delves into the world of cannabis and explores the various ways it can contribute to our well-being, including pain management, stress relief, and sleep aid. We’ll also discuss the growing presence of cannabis in alternative medicine and the emerging trends within the wellness industry.

Despite recent challenges, the California Cannabis GDP could still support a small island nation.

California’s marijuana industry continues to dominate as the world’s largest cannabis market, despite facing financial and tax challenges. According to the recently published MJBiz Factbook, the state is estimated to generate nearly $5.9 billion in legal recreational and medical marijuana sales in 2023. To put this into perspective, the revenue from marijuana sales in California could support the economy of a small island nation.

Exploring Cannabis Consumer Archetypes in America: Trends and Insights for 2023

New Frontier Data presents the 2023 archetypes of cannabis consumers in America. The report highlights nine consumer archetypes based on the latest consumer survey data. The first archetype is Savvy Connoisseurs, comprising 13% of consumers. They are heavy cannabis users who consume it multiple times a day for various medical and recreational purposes. They obtain cannabis from both legal sources like dispensaries and informal channels such as friends or illicit dealers. Savvy Connoisseurs are the highest spenders and often purchase cannabis weekly.

Newsletter

New Jersey Cannabis Regulators Propose New Permits to Facilitate Research Partnerships with Dispensaries

New Jersey Cannabis Regulators Propose New Permits to Facilitate Research Partnerships with Dispensaries

New Jersey’s cannabis regulatory authorities are currently open to public feedback regarding an innovative proposal aimed at introducing a novel permit. This permit would enable “clinically focused” dispensaries to collaborate with research institutions, facilitating comprehensive studies on cannabis using the products they cultivate and sell to patients.

The New Jersey Cannabis Regulatory Commission (CRC) is actively seeking to amend the state’s existing marijuana legislation to establish what they are terming “clinical registrant permits.” These permits are designed to encourage more targeted research into the medical benefits of cannabis, particularly in therapeutic or palliative contexts. Importantly, this research would not rely on externally sourced cannabis products.

Under the proposed system, clinical registrants would possess the same privileges as traditional dispensary license holders. However, they would also have the unique capability to form “written contractual relationships with academic medical centers in their respective regions.” These partnerships would empower them to engage in clinical research centered around the use of medical cannabis.

In essence, this groundbreaking initiative would permit researchers to conduct clinical trials involving patients within the state, utilizing the very cannabis products that patients purchase from dispensaries.

The proposed rules state, “A clinical registrant may dispense usable medical cannabis and medical cannabis products, in any form authorized by an institutional review board (IRB), directly to an academic medical center as part of a research study.” Additionally, academic medical centers engaging in such research would be required to handle cannabis items with the same high standards applied to other patient medications.

It’s important to note that clinical registrants would be prohibited from simultaneously holding non-clinical medical cannabis cultivation, manufacturing, or dispensary permits, or a personal-use cannabis business license. Furthermore, academic research institutions partnering with clinical registrants would be restricted from accepting “anything of value” from these clinically focused dispensaries, except for reasonable compensation stipulated in the research contract.

The public is invited to provide comments on this proposal until October 6, with the CRC emphasizing that these new rules could substantially benefit society by achieving the statutory objective of ensuring safe access to medical cannabis for patients in need through the introduction of this additional permit type.

This novel permit type could play a pivotal role in addressing research gaps caused by federal cannabis prohibition. Researchers have been burdened by stringent registration procedures with the Drug Enforcement Administration (DEA) to access cannabis for studies. Additionally, they have had to rely on government-grown cannabis products that are often of inferior quality and potency compared to those available in state-legal cannabis markets.

This issue was a point of discussion during a recent meeting among representatives from several federal agencies. Nora Volkow, the Director of the National Institute on Drug Abuse (NIDA), has herself expressed support for allowing researchers to study cannabis from state-licensed retailers.

While a bill signed by President Joe Biden last year aimed to streamline the cannabis research process, it lacked provisions found in a House version that would have granted scientists access to cannabis from licensed dispensaries.

Many of the research roadblocks surrounding cannabis could potentially be resolved if the U.S. Department of Health and Human Services (HHS) recommendation to reclassify the substance from Schedule I to Schedule III under the Controlled Substances Act (CSA) is accepted. However, it remains uncertain whether the Drug Enforcement Administration (DEA) will endorse this recommendation.

Source: Marijuana Moment

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Unleashing the Magic: The Rise of Cannabis Edibles

Ladies and gentlemen, gather around and prepare to have your taste buds delighted and your senses stimulated. The days of risky and uncertain cannabis-infused edibles are a thing of the past, replaced by a new era of standardized and properly labeled treats. Join me on this exhilarating journey as we explore the fascinating ascent of edibles in the continuously evolving landscape of cannabis.

Green Wave Rising: Navigating the Global Cannabis Legalization Landscape

In recent years, there has been a growing global shift towards the legalization of cannabis. This remarkable trend has sparked intense debates and discussions surrounding the implications of such legislative changes. As cannabis becomes more widely accepted, it is crucial to examine the current state of cannabis legalization worldwide, highlighting recent developments, legislative changes, and the impact of these changes on society, the economy, and public health. By exploring the potential benefits and challenges of cannabis legalization, we can gain a better understanding of this evolving landscape.

A Green Opportunity: Advertising in the Cannabis Industry

The cannabis industry has undergone a remarkable transformation in recent years, evolving from a taboo, underground market to a legitimate, booming industry. As legalization continues to spread across the United States and other parts of the world, businesses within the cannabis sector are faced with a unique challenge: how to effectively advertise their products and services in a heavily regulated and stigmatized environment.

Newsletter

Blue Dream’s Two Decades of Influence: Unraveling the Origins and Impact

Blue Dream’s Two Decades of Influence: Unraveling the Origins and Impact

From Haze to Skunk, OG to Cookies, the cannabis market has been shaped by remarkable strains that encapsulate their respective eras. Among them, Blue Dream emerged as a defining cultivar around 2003, reigning until approximately 2011 when shifting market preferences opened the door for a new strain to take the spotlight. As we commemorate two decades of Blue Dream’s legacy, it’s intriguing to note that despite its celebrated status as the “most popular strain on the planet” at one point, there remains a surprising shroud of uncertainty surrounding its true origins and characteristics.

Unveiling Blue Dream’s Genetic Ancestry

The enigmatic origins of Blue Dream continue to mystify experts and enthusiasts alike. While the identity of its original breeder remains a mystery, a prevailing consensus exists about its genetic lineage. Renowned cannabis breeder Ed Rosenthal, as reported by Ellen Holland in her seminal piece on Blue Dream’s history for High Times, revealed that this strain is a hybrid of “Haze and DJ Short’s Blueberry.” This assertion is corroborated by various online sources. Yet, a mild debate persists regarding the specific Blueberry cultivar and the type of Haze involved. Jason Matthys, founder of Equilibrium Genetics, has disclosed that the Haze used might have been from Corralitos, hinting at the Santa Cruz Haze rather than Super Silver Haze. The subtle distinctions in these genetics cast intriguing shadows on Blue Dream’s true lineage.

Unraveling the Mystery of a “Second” Blue Dream

Whispers of not one, but two variants of Blue Dream have circulated within cannabis circles. While some argue that one version leans more toward sativa while the other veers indica, clarity eludes this speculation. Eva Erikson of Haze Valley Nursery shared insights into the rumor, suggesting that the “imposter Blue Dream” could be an offshoot bred from the original. This discrepancy might arise from the choice between DJ Short’s Blueberry and Super Silver Haze in the breeding process, or it could even reflect variations influenced by environmental factors rather than genetic differences.

Architects of Blue Dream’s Success

Unveiling the mastermind behind Blue Dream’s meteoric rise proves equally elusive. Various leads have been pursued, yet the original breeder remains concealed. Speculations abound, with some tracing its lineage to the patient group WAMM, while others highlight the hills above Bonny Doon as a probable birthplace. The cannabis community’s efforts to pinpoint the true creator have been met with intriguing dead-ends, leaving a sense of enduring mystery.

A Symphony of Flavors and Terpenes

Blue Dream’s flavor profile is a harmonious blend of its parent strains, with the Blueberry influence taking precedence over Haze. Descriptions range from simple blueberry notes to intricate comparisons with blueberry muffins, occasionally punctuated by hints of sandalwood or musk from the Haze side. Terpene analyses often reveal dominant compounds like beta myrcene, alpha pinene, and beta caryophyllene, imparting sweet, spicy, and woody aromas. Interestingly, blueberries themselves contain cineole and linalool, shedding light on the diverse bouquet within Blue Dream’s fragrance.

The Rise, Fall, and Resurgence

Blue Dream’s narrative reflects the tumultuous Green Rush era, where its popularity skyrocketed due to its ease of cultivation, high THC content, and enticing aroma. However, overproduction during this phase led to diluted quality as novice cultivators rushed the growing process. Despite encountering a decline due to this influx of subpar offerings, Blue Dream is experiencing a revival. Craig and Melanie Johnson, growers at Alpenglow Farms, concur that quality suffered due to rapid harvesting, preventing the strain from reaching its full potential. The market’s evolution since the Green Rush is breathing new life into Blue Dream, as enthusiasts seek the authentic experience of this classic cultivar.

Blue Dream’s Legacy

The story of Blue Dream, spanning two decades, is one of enduring allure and transformation. While questions linger about its genetic lineage and originator, this strain’s impact on the cannabis landscape remains undeniable. A harmonious fusion of flavors, terpenes, and effects contributed to its initial success, only to be challenged by quality concerns during the Green Rush. Now, as the cannabis industry matures, Blue Dream is poised for a triumphant resurgence, a reminder of its enduring legacy amid an ever-evolving market.

 

Source: High Times

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Cannabis Milestone: Vermont’s Thriving Marketplace Surpasses $100 Million in Sales

Vermont’s cannabis marketplace is celebrating its first year of operation, and the results are nothing short of impressive. With projections indicating retail sales for the current fiscal year reaching over $100 million, the state has reaped more than $20 million in additional revenue. This milestone underscores the success of Vermont’s foray into regulated cannabis sales.

Despite recent challenges, the California Cannabis GDP could still support a small island nation.

California’s marijuana industry continues to dominate as the world’s largest cannabis market, despite facing financial and tax challenges. According to the recently published MJBiz Factbook, the state is estimated to generate nearly $5.9 billion in legal recreational and medical marijuana sales in 2023. To put this into perspective, the revenue from marijuana sales in California could support the economy of a small island nation.

Exploring Cannabis Consumer Archetypes in America: Trends and Insights for 2023

New Frontier Data presents the 2023 archetypes of cannabis consumers in America. The report highlights nine consumer archetypes based on the latest consumer survey data. The first archetype is Savvy Connoisseurs, comprising 13% of consumers. They are heavy cannabis users who consume it multiple times a day for various medical and recreational purposes. They obtain cannabis from both legal sources like dispensaries and informal channels such as friends or illicit dealers. Savvy Connoisseurs are the highest spenders and often purchase cannabis weekly.

Newsletter

Missouri Division of Cannabis Regulation Initiates Recall of 62,000 Cannabis Products: An In-Depth Look at the Delta Extraction Case and Industry Lessons

Missouri Division of Cannabis Regulation Initiates Recall of 62,000 Cannabis Products: An In-Depth Look at the Delta Extraction Case and Industry Lessons

The Missouri Division of Cannabis Regulation (DCR) has recently taken a significant step in the cannabis industry by issuing a recall of more than 62,000 cannabis products manufactured by Delta Extraction, LLC. The reason behind this recall lies in the fact that these products were not being compliantly tracked in the statewide track and trace system known as METRC. This failure to adhere to tracking protocols created a situation where the DCR could not verify the origins of these products – whether they were sourced from marijuana cultivated within Missouri and had undergone the necessary testing procedures.

The scope of this recall encompasses a wide range of cannabis-infused products, including tinctures, vape cartridges, gel capsules, tablets, and other similar items. To ensure public safety, the DCR has strongly recommended that consumers who have purchased any of these affected products take appropriate action. They can either discard these items or return them to the dispensary where they were originally purchased. Importantly, the DCR has reassured consumers that these returns will not impact their established monthly purchase limits, providing a degree of comfort to those affected.

The DCR has been proactive in promoting awareness among consumers regarding the risks associated with marijuana products that have not been appropriately tracked in the METRC system. By urging consumers to follow the prescribed disposal or return procedures, the DCR is attempting to safeguard the well-being of the public.

Additionally, the DCR has emphasized the significance of reporting any adverse reactions related to the use of these products. They have provided channels for reporting such reactions, including email and an online complaint form, underlining their commitment to ensuring consumer safety.

The context leading up to this recall involves a lengthy hearing at the Administrative Hearing Commission. During this hearing, Delta Extraction challenged the immediate suspension of its license by the Missouri Department of Health and Senior Services (DHSS). The suspension followed the discovery that Delta Extraction had incorporated out-of-state hemp-derived THCa into its marijuana products. THCa is the non-psychoactive compound in marijuana that converts into THC when heated, producing the characteristic “high.”

Delta Extraction’s representative, Jack Maritz, asserted that the distillation process allowed for the utilization of out-of-state hemp-derived THCa. The company’s position was based on previous state regulations that seemed to permit this practice. However, the state counterargued that recent regulations had clarified the prohibition of such practices. The outcome of the hearing remains pending, as the Administrative Hearing Commission has yet to decide on the reinstatement of Delta Extraction’s license.

Rachael Herndon, Delta’s chief operational officer, highlighted the adverse effects of the license suspension on the company’s reputation and financial standing. She stated, “Our reputation was damaged, and we had over $10 million in product on our site immediately locked up.”

This recall serves as a poignant reminder to both cannabis producers and consumers about the ever-evolving landscape of rules and regulations in the cannabis industry. The rapid shifts in policies underline the necessity for all stakeholders – including manufacturers, dispensaries, patients, and consumers – to remain diligently informed about the most current guidelines and procedures. By staying up-to-date, the industry can collectively work towards maintaining high standards of safety and compliance.

Source: Beardbrospharms

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Navigating the Path to Stability: Receivership as an Alternative to Bankruptcy for Struggling Cannabis Businesses

As the cannabis industry continues to experience rapid growth and profit potential, businesses operating within this space face unique challenges and complexities. Financial distress may strike even the most promising cannabis enterprises, leaving them searching for viable solutions beyond traditional bankruptcy protection. In such cases, receivership emerges as an equitable remedy—a legal process that empowers a court-appointed receiver to take control of a distressed business. In this article, we will delve into what receivership entails and explore its significance as an alternative to bankruptcy for struggling cannabis companies.

How to Calculate the THC Content in Your Cannabis-Infused Recipes

If you are someone who loves cooking and is also a fan of cannabis, then cannabis-infused recipes might be something that you enjoy. However, it is important to calculate the THC content in your cannabis-infused recipes to ensure that you are consuming the right dosage. In this article, we will guide you through the process of calculating the THC content in your cannabis-infused recipes with the help of Yes Cannabis.

Spotify Breaks Ground with First-Ever Cannabis Ads in Partnership with Cresco Labs

Spotify, the world’s leading music streaming service, has always been known for its bold and innovative approach. In a groundbreaking move, Spotify has become the first streaming platform to embrace cannabis advertising through its new collaboration with Cresco Labs (CRLBF).

Newsletter

Revolutionary Shift: US Health Department Proposes Reclassifying Marijuana from Schedule I to Schedule III

Revolutionary Shift: US Health Department Proposes Reclassifying Marijuana from Schedule I to Schedule III

In a groundbreaking move that has the potential to reshape the landscape of cannabis regulations, the U.S. Department of Health and Human Services (HHS) has taken a bold step by formally recommending the reclassification of marijuana from Schedule I to Schedule III under federal law. This historic decision signifies a seismic shift in perspective, indicating that the nation’s premier health agency no longer views cannabis as a substance with high abuse potential and zero medical value.

Following an intensive scientific investigation into cannabis, which was conducted as a response to a directive from President Joe Biden, the HHS has conveyed its verdict to the Drug Enforcement Administration (DEA): cannabis should be repositioned from the confines of Schedule I to the more accommodating Schedule III of the Controlled Substances Act (CSA). Although this suggestion isn’t binding, the amalgamation of thorough scientific analysis and a growing swell of political support for cannabis reform may wield substantial influence over the DEA’s final decision

By classifying cannabis as a Schedule III drug, the plant would still remain prohibited at the federal level. However, this recalibration would have far-reaching consequences, particularly for researchers who have long decried the burdensome barriers erected by the Schedule I categorization, which impedes access for critical studies

An HHS spokesperson elaborated on this significant development: “Grounded in data and scientific exploration, the HHS promptly heeded President Biden’s directive to Secretary Becerra, furnishing its recommendation for rescheduling cannabis to the DEA on August 29, 2023.” The spokesperson emphasized the efficiency of this administrative procedure, which was accomplished in less than 11 months, underscoring the department’s collaborative spirit and commitment to expeditiously complete a comprehensive scientific evaluation for wider dissemination.

This shift to Schedule III would also have the power to unlock tax incentives within the burgeoning marijuana industry that are currently off-limits.

Confirming this milestone, a DEA spokesperson conveyed, “DEA has received a communiqué from the Department of Health and Human Services, sharing its conclusions and suggestions regarding marijuana scheduling, in line with President Biden’s request for a review.” As part of this process, the HHS diligently carried out a comprehensive scientific and medical assessment, a foundational aspect of the DEA’s ultimate authority to reclassify or retain the classification of a drug within the Controlled Substances Act. The DEA is now poised to embark on its evaluation process.

The vital scientific review that paved the way for the Schedule III recommendation was spearheaded by the Food and Drug Administration (FDA) under the HHS’s guidance.

According to initial reports from Bloomberg, the HHS Assistant Secretary for Health, Rachel Levine, who ardently advocated for medical cannabis during her tenure as Pennsylvania’s health secretary prior to joining the Biden administration, dispatched a letter to the DEA that explicitly referenced the FDA’s meticulous review.

This momentous stride comes after a mere two months since HHS Secretary Xavier Becerra revealed to Marijuana Moment that the agency aimed to conclude the review by year’s end.

A spokesperson from the White House emphasized the independent nature of the administrative process: “The administrative process is independently managed by HHS and DOJ, driven by evidence. Thus, the President’s team will not offer commentary on the agency’s recommendation at this juncture.”

White House Press Secretary Karine Jean-Pierre reiterated this point during a recent briefing, highlighting the president’s stance on the issue. She affirmed that President Biden sought an independent administrative review conducted by the HHS and DOJ, underscoring that the forthcoming decisions would be rooted in evidence and the best interests of public health.

This move to reclassify marijuana from Schedule I to Schedule III holds significant practical and political ramifications, contingent on the DEA’s alignment with the HHS recommendation.

For researchers, this change would signal the end of the cumbersome DEA registration process, a requirement for accessing cannabis for studies as a Schedule I drug. Notably, Director Nora Volkow of the National Institute on Drug Abuse (NIDA) has expressed concerns about these barriers, and it is reported that NIDA has endorsed the HHS’s recommendation for rescheduling marijuana.

From a business standpoint, this reclassification would empower cannabis enterprises to claim federal tax deductions—an option currently out of reach for businesses engaged in the sale of Schedule I or II drugs. The higher effective tax rate imposed on the cannabis industry could potentially diminish with this shift, a change that various state governments have already taken the initiative to address through state-level tax relief measures.

On the political front, such a reclassification could serve as a crowning achievement for the president, who would be credited with overseeing a monumental reform. This administrative evaluation, which could lead to rescheduling over five decades after cannabis was initially categorized as a Schedule I drug during the “war on drugs,” could also lend momentum to congressional endeavors aimed at further reforming federal cannabis laws. As lawmakers return from the August recess, they could point to the HHS’s recommendation as tangible evidence of the urgency to normalize and regulate the cannabis industry.

The HHS spokesperson emphasized the final stages of this process: “While HHS’s scientific and medical evaluation is binding on DEA, the scheduling recommendation is not.” The DEA, equipped with the ultimate authority to schedule, reschedule, or remove a drug from scheduling within the CSA, will undergo a meticulous rulemaking process, complete with a period for public input, before finalizing any scheduling decisions.

Despite the aspirations of advocates for a complete descheduling of cannabis, the HHS review’s outcome is a reclassification from Schedule I to Schedule III. This, however, has raised concerns about whether the FDA could take a more hands-on role in the regulation of cannabis. A former top FDA official, Howard Sklamberg, who previously chaired the agency’s Marijuana Working Group and foresaw the Schedule III recommendation, dismissed such fears, asserting that the FDA and DOJ have adopted a largely non-interventionist stance with the burgeoning legalization movement even while cannabis remains a Schedule I substance. Sklamberg contended that it defied reason to presume the agencies would abruptly intensify enforcement actions if cannabis were shifted to a less restrictive category.

In a separate development, Rep. Matt Gaetz (R-FL) has pressed DEA Administrator Anne Milgram for clarity regarding the president’s directive on the marijuana scheduling review. Gaetz seeks a copy of the letter allegedly sent by President Biden to the attorney general and HHS secretary, along with an update on any communication between Milgram and HHS regarding the evaluation timeline.

The journey toward reclassifying marijuana from Schedule I to Schedule III is replete with implications that extend across multiple dimensions—practical, political, and scientific. This momentous decision marks a significant stride towards cannabis normalization and underscores the dynamic interplay between scientific inquiry, political will, and regulatory evolution.

Source: Marijuana Moment

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Missouri Division of Cannabis Regulation Initiates Recall of 62,000 Cannabis Products: An In-Depth Look at the Delta Extraction Case and Industry Lessons

The Missouri Division of Cannabis Regulation (DCR) has recently taken a significant step in the cannabis industry by issuing a recall of more than 62,000 cannabis products manufactured by Delta Extraction, LLC. The reason behind this recall lies in the fact that these products were not being compliantly tracked in the statewide track and trace system known as METRC. This failure to adhere to tracking protocols created a situation where the DCR could not verify the origins of these products – whether they were sourced from marijuana cultivated within Missouri and had undergone the necessary testing procedures.

How to Calculate the THC Content in Your Cannabis-Infused Recipes

If you are someone who loves cooking and is also a fan of cannabis, then cannabis-infused recipes might be something that you enjoy. However, it is important to calculate the THC content in your cannabis-infused recipes to ensure that you are consuming the right dosage. In this article, we will guide you through the process of calculating the THC content in your cannabis-infused recipes with the help of Yes Cannabis.

Rethinking Cannabis Potency

According to recent survey data by New Frontier Data, there is a wide range of effective doses for cannabis across different populations. This means that some people can feel the effects of just 1mg of THC, while others may not notice any effects until they consume 20 or 30mg of THC. Interestingly, this variation is more significant than the variation in tolerance levels for commonly used substances like coffee and alcohol. In fact, a 30x difference in the effective dose of wine or coffee is unimaginable.

Newsletter